27392220|t|Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy
27392220|a|Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.
27392220	12	29	Cancer Stem Cells	T017	UMLS:C1956422
27392220	33	36	CML	T038	UMLS:C0023473
27392220	54	69	Transcriptional	T038	UMLS:C0040649
27392220	70	77	Therapy	T058	UMLS:C0087111
27392220	78	86	Leukemia	T038	UMLS:C0023418
27392220	87	97	stem cells	T017	UMLS:C1956422
27392220	99	103	LSCs	T017	UMLS:C1956422
27392220	130	139	therapies	T058	UMLS:C0087111
27392220	154	178	chronic myeloid leukemia	T038	UMLS:C0023473
27392220	180	183	CML	T038	UMLS:C0023473
27392220	226	243	molecular network	T038	UMLS:C1148560
27392220	257	260	CML	T038	UMLS:C0023473
27392220	261	264	LSC	T017	UMLS:C1956422
27392220	265	273	survival	T038	UMLS:C0007620
27392220	335	361	transcriptional regulators	T103	UMLS:C0040648
27392220	363	366	p53	T017	UMLS:C0079419
27392220	371	376	c-Myc	T103	UMLS:C0314684
27392220	399	410	eradication	T038	UMLS:C2248542